| Abstract | This review is dealing with currently available medications used in the treatment of obesity. Unfortunately currently available drugs did not prove effective in the long term treatment of obese patients. Fenfluramin and D-Fenfluramin has been withdrawn from the market because of severe side effects as pulmonary hypertension and valvular heart disease. Sibutramin, a serotonin noradrenalin reuptake inhibitor, will be available this year. Orlistat, an inhibitor of pancreatic lipases, has proven effective for weight reduction in obese patients. New drugs as alpha 2-adrenergic antagonists, cholecystokinin, neuropeptide y, bombesin and leptin are in the pipeline. |
| Authors | J G Wechsler
(Affiliation: Inneren Abteilung des Krankenhauses, Barmherzigen Brüder, München, Deutschland.)
|
| Journal | Acta medica Austriaca
(Acta Med Austriaca)
Vol. 25
Issue 4-5
Pg. 138-41
( 1998)
ISSN: 0303-8173 AUSTRIA |
| Vernacular Title | Medikamentöse Therapie der Adipositas. |
| PMID | 9879389
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Animals
- Appetite Depressants
(adverse effects, therapeutic use)
- Body Weight
(drug effects)
- Humans
- Obesity
(drug therapy, etiology)
|
